Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR‐PAH study: Baseline characteristics and risk factors

• DOI: 10.1111/1756-185x.13478
• Publication Date: 2019-02-12T01:09:19Z
• Authors: Na Zhang; Mengtao Li; Junyan Qian; Qian Wang; Jiuliang Zhao; Zhenwen Yang; Zhuang Tian; Xiao Zhang; Xiaoxia Zuo; Miaojia Zhang; Ping Zhu; Shuang Ye; Wei Zhang; Yi Zheng; Wufang Qi; Yang Li; Zhuoli Zhang; Feng Ding; Jieruo Gu; Yi Liu; Wei Wei; Xiaofeng Zeng
• Keywords: Baseline (sea)

Abstract Aim Pulmonary arterial hypertension (PAH) is a complex and devastating complication of systemic lupus erythematosus (SLE). We sought to describe the baseline characteristics right heart catheterization (RHC)‐confirmed SLE‐associated PAH identify risk factors for in SLE patients. Methods A multicenter, cross‐sectional study was conducted using Chinese Treatment Research group (CSTAR) registry. Baseline data patients with without were collected compared. Risk among identified. Results total 292 enrolled. RHC used reveal hemodynamic features, including mean pulmonary pressure (46.2 ± 12.0 mm Hg), wedge (7.84 3.92 vascular resistance (10.86 5.57 Wood units), cardiac index (2.77 0.91 L/min × m 2 ). multivariate logistic regression analysis showed that serositis (odds ratio [OR] = 5.524, 95% CI 3.605‐8.465, P < 0.001), anti‐ribonucleoprotein (RNP) antibody positivity (OR 13.332, 9.500‐18.710, diffusion capacity carbon monoxide lung (DLCO)/%Pred <70% 10.018, 6.619‐15.162, 0.001) independent predictors PAH. recommend transthoracic echocardiography (TTE) perform early screening who have serositis, anti‐RNP positivity, or DLCO/%Pred <70%. suggested suspected having Once diagnosis SLE‐PAH confirmed, evaluation treatment should immediately begin. Conclusion Overall, we performing TTE antibodies, <70%, even relatively stable condition according disease activity index.